Please try another search
Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.
Name | Age | Since | Title |
---|---|---|---|
Vicki L. Sato | 75 | 2016 | Independent Chairman |
George A. Scangos | 76 | 2017 | Director |
Thomas O. Daniel | 70 | 2017 | Scientific Advisor |
Robert J. More | 56 | 2016 | Independent Director |
Sona Saira Ramasastry | 48 | 2019 | Independent Director |
Jeffrey S. Hatfield | 66 | 2020 | Independent Director |
Robert Taylor Nelsen | 62 | 2016 | Independent Director |
Marianne De Backer | 55 | 2023 | CEO & Director |
Lawrence Corey | 76 | 2016 | Co-Founder & Scientific Advisor |
Louis J. Picker | - | - | Co-Founder & Scientific Advisor |
Klaus Frueh | 64 | 2016 | Co-Founder & Scientific Advisor |
Jeffrey A. Bluestone | 71 | - | Scientific Advisor |
Charles M. Rice | - | - | Scientific Advisor |
Susanna Naggie | - | - | Scientific Advisor |
Jeffrey V. Ravetch | 73 | - | Scientific Advisor |
George H. Poste | 80 | - | Scientific Advisor |
Emilio A. Emini | 71 | 2015 | Scientific Advisor |
Francis V. Chisari | - | - | Scientific Advisor |
Norbert W. Bischofberger | 68 | 2024 | Independent Director |
Charles Elliott Sigal | 72 | 2020 | Independent Director |
Janet Napolitano | 66 | 2020 | Independent Director |
Ramy Farid | 59 | 2024 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review